Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Experimental validation of rotating detonation for rocket propulsion.
Bennewitz JW, Burr JR, Bigler BR, Burke RF, Lemcherfi A, Mundt T, Rezzag T, Plaehn EW, Sosa J, Walters IV, Schumaker SA, Ahmed KA, Slabaugh CD, Knowlen C, Hargus WA Jr. Bennewitz JW, et al. Among authors: walters iv. Sci Rep. 2023 Aug 30;13(1):14204. doi: 10.1038/s41598-023-40156-y. Sci Rep. 2023. PMID: 37648704 Free PMC article.
Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P, Denizeau J, Sedlik C, Gerber-Ferder Y, Fiore F, Akyol R, Brousse C, Kramer R, Walters I, Carlioz S, Salmon H, Malissen B, Dalod M, Piaggio E, Manel N. Jneid B, et al. Among authors: walters i. Sci Immunol. 2023 Jan 13;8(79):eabn6612. doi: 10.1126/sciimmunol.abn6612. Epub 2023 Jan 13. Sci Immunol. 2023. PMID: 36638189
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA, Pawlitzky I, Grosios K, Gileadi U, Middleton MR, Gerritsen WR, Mehra N, Rivoltini L, Walters I, Figdor CG, Ottevanger PB, de Vries IJM. Creemers JHA, et al. Among authors: walters i. BMJ Open. 2021 Nov 30;11(11):e050725. doi: 10.1136/bmjopen-2021-050725. BMJ Open. 2021. PMID: 34848513 Free PMC article.
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.
Bloom AC, Bender LH, Tiwary S, Pasquet L, Clark K, Jiang T, Xia Z, Morales-Kastresana A, Jones JC, Walters I, Terabe M, Berzofsky JA. Bloom AC, et al. Among authors: walters i. Oncoimmunology. 2019 Jul 16;8(10):e1625687. doi: 10.1080/2162402X.2019.1625687. eCollection 2019. Oncoimmunology. 2019. PMID: 31646070 Free PMC article.
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G. Jones RL, et al. Among authors: walters i. Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12. Eur J Cancer. 2019. PMID: 31522033 Free PMC article. Clinical Trial.
61 results